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Abstract (Word count:250) 
 
Aims: 
Genome-wide association studies (GWAS) identified many common type 2 diabetes-associated 
variants, mostly found at the intronic or intergenic regions. Recent advancement of exome array 
genotyping platforms have opened up a novel means for detecting the associations of low-frequency 
or rare coding variants with type 2 diabetes. We conducted an exome-chip association analysis to 
identify additional type 2 diabetes susceptibility variants in the Chinese population. 
 
Methods: 
An exome-chip association study was conducted by genotyping 5640 Hong Kong Chinese individuals 
using a custom Asian Exome-chip. Single variant association analysis was conducted on 77,468 single 
nucleotide polymorphisms (SNPs). Fifteen SNPs were subsequently genotyped for replication 
analysis in an independent Chinese cohort comprising 12,362 Guangzhou individuals. A combined 
analysis involving 7189 cases and 10,813 controls was performed. 
 
Results: 
In the discovery stage, an Asian-specific coding variant rs2233580 (p.Arg192His) in PAX4, and 2 
variants at the known loci, CDKN2B-AS1 and KCNQ1, were significantly associated with type 2 
diabetes at exome-wide significance (pdiscovery<6.45x10
-7
). The risk allele (T) of PAX4 rs2233580 was 
associated with a younger age of diabetes diagnosis. This variant was replicated in an independent 
cohort and demonstrated a stronger association that reached genome-wide significance (pmeta=3.74x10
-
15
) in the combined analysis.  
 
Conclusions: 
We identified the association of a PAX4 Asian-specific missense variant rs2233580 with type 2 
diabetes in an exome-chip association analysis, supporting the involvement of PAX4 in the 
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pathogenesis of type 2 diabetes. Our findings are suggestive of PAX4 being a possible effector gene of 
the 7q32 locus previously identified from GWAS amongst Asians.  
 
Key words: Asian-specific; Exome-chip association analysis; PAX4; Type 2 diabetes  
 
Abbreviations: 
CRISPS  Hong Kong Cardiovascular Risk Factor Prevalence Study 
CSN1S1  Casein Alpha S1 
FGF21   Fibroblast growth factor 21 
FPG   Fasting plasma glucose 
GBCS   Guangzhou Biobank Cohort Study 
GWAS   Genome-wide association studies 
HKU-TRS  The University of Hong Kong Theme-based Research Scheme 
HKWDR  Hong Kong West Diabetes Registry 
MAF   Minor allele frequency 
MODY   Maturity-onset diabetes of the young 
PAX4   Paired Box Gene 4 
PC   Principal component 
SNP   Single nucleotide polymorphism 
TTBK2   Tau-tubulin-kinase 2  
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Introduction 
 
Type 2 diabetes is a common disease resulting from the complex interactions between multiple 
genetic and environmental factors. Insights into the genetic basis of type 2 diabetes will facilitate the 
discovery of novel treatment targets. Since 2007, the success in genome-wide association studies 
(GWAS) has led to the identification of a large number of independent loci for type 2 diabetes. 
However, the disease-susceptibility single nucleotide polymorphisms (SNPs) identified from these 
GWAS are common variants which tend to confer relatively small effect sizes, altogether accounting 
for only 10 to 15% of the type 2 diabetes heritability [1]. The functional consequences of these 
susceptibility variants, which are mostly present in intronic or intergenic regions, remained difficult to 
interpret. In the past few years, the role of low-frequency (minor allele frequency [MAF] =1%-5%) 
and rare (MAF<1%) coding variants with various complex traits [2-7] is being increasingly studied. It 
has been suggested that most current rare variants were introduced by mutational events during the 
recent explosive growth of the human population [8, 9]. These rare variants are believed to confer a 
greater effect than the common variants due to the limited time for purifying selection to act [9, 10]. 
The majority of efforts to reveal type 2 diabetes susceptibility variants have been made in populations 
of European ancestry. Utilising the advanced technologies, such as the exome-chip and whole 
genome/exome-sequencing, researchers have detected associations of additional novel coding variants, 
both common and rare, for type 2 diabetes [4, 5] and several quantitative glycaemic traits, such as 
fasting glucose and insulin levels in European populations [3, 6, 7]. As samples of European ancestry 
represent only a subset of human genetic variations [11], the risk variants in other populations are 
likely to be insufficiently characterised. A genome-wide trans-ancestry meta-analysis reported several 
type 2 diabetes-susceptibility variants which showed significant difference in effect sizes and 
associations in different populations [12]. For instances, the effect size of TCF7L2 rs7903146 was 
higher in Europeans than in East Asians; and the association signal of PEPD rs3786897 was specific 
to the populations of East Asians, while the association signal of KLF14 rs13233731 was only 
significant in the European samples [12]. Such observations highlight the importance of conducting 
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association analysis in non-European populations to detect novel loci affecting the risk of type 2 
diabetes.  
 
The advancement in array-based genotyping technology, such as exome arrays, has provided a more 
cost effective approach, compared to whole-genome or exome sequencing, for assessing the 
association of rare and low-frequency coding variants which may be population-specific. In a joint 
collaboration study, our group has recently reported several novel or Asian-specific coding variants 
associated with blood lipids [2], using a tailored Illumina HumanExome BeadChip (Asian Exome-
chip [13]). In the present study, we aimed to detect novel loci for type 2 diabetes in the Chinese 
population using the Asian Exome-chip. We first conducted an exome-chip association analysis based 
on 5640 participants from the University of Hong Kong Theme-based Research Scheme (HKU-TRS) 
cohort, and genotyped 15 SNPs for replication in an independent Southern Han Chinese cohort from 
Guangzhou (n=12,362).  
 
Methods and Materials 
Participants 
Discovery cohort:  
The discovery stage involved a total of 5640 Southern Han Chinese participants (3652 cases and 1988 
controls) from the HKU-TRS cohort who participated in a previous exome-chip association study for 
blood lipid traits [2]. The study participants were recruited from the Hong Kong West Diabetes 
Registry (HKWDR) [14]; the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) [15] 
and the Chinese CAD cohort of the Queen Mary Hospital in Hong Kong. Details of the corresponding 
cohorts have been previously reported [2]. Type 2 diabetes cases were defined as fulfilling at least one 
of the following criteria: fasting plasma glucose (FPG)≥7mmol/l; or 2-hr glucose during oral glucose 
tolerance test (OGTT)≥11.1mmol/l; or taking glucose-lowering agents; or physician-diagnosed 
diabetes. All controls had no documented history of diabetes and were not on treatment for diabetes. 
Written informed consent was obtained from each participant and the study protocol was approved by 
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the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West 
Cluster. 
 
Replication cohort:  
The replication stage involved a total of 12,362 Southern Han Chinese participants (3537 cases and 
8825 controls) of the Guangzhou Biobank Cohort Study (GBCS) (ESM Table 1). The clinical 
characteristics and glycaemic status were based on cross-sectional data obtained at the time of blood 
sample collection. Details of GBCS have been described previously [16]. In brief, GBCS is a 
collaborative project between Guangzhou Number 12 Hospital, the University of Hong Kong and the 
University of Birmingham. The GBCS was established to examine the effect of genetic and 
environmental influences on health problems and development of chronic diseases. The baseline 
recruitment was conducted from 2003 to 2008 (n=30,519; aged 50 or above) in Guangzhou [17]. 
Participants were invited to participate in the second examination from August 2008 to December 
2012. The present study included participants who attended the second examination and had sufficient 
information for determination of type 2 diabetes status. Type 2 diabetes cases were defined as 
fulfilling at least one of the following criteria: FPG≥7mmol/l; or 2-hr glucose during 
OGTT≥11.1mmol/l; or haemoglobin A1c (HbA1c) ≥6.5% (47.5mmol/mol); or taking glucose-
lowering agents; or self-reported physician-diagnosed diabetes. All controls were not on treatment for 
diabetes, had no documented history of diabetes and had FPG <6.1mmol/l and 2-hr glucose during 
OGTT<7.8mmol/l. Written informed consent was obtained from each participant and the study 
protocol was approved by the Guangzhou Medical Ethics Committee of the Chinese Medical 
Association. 
 
Genotyping and data quality control 
Discovery stage:  
All participants were genotyped using a custom Asian Exome-chip which was a specially designed 
exome array with an add-on content of 58,317 variants in addition to the standard content of the 
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Infinium HumanExome BeadChip (HumanExome-12v1_A; Illumina, CA). Detailed description of the 
Asian Exomechip design has been presented elsewhere [2, 13]. Briefly, the standard content of the 
exome array includes 242,901 markers, including>200,000 protein-altering variants identified from 
approximately 12,000 sequenced genomes and exomes of primarily European ancestry; and >20,000 
non-exonic variants contributed by multiple consortia, such as NHLBI Exome Sequencing Project; 
and variants designed for ancestry differentiation, sample tracking and for establishing segments of 
identity by descent (http://genome-sph.umich.edu/wiki/Exome_Chip_Deisgn; accessed 1 May 2016). 
The European based design has led to an under-representation of the non-European genomes and 
thereby limited the coverage of low frequency variants among the non-European populations. With a 
view to allow comprehensive genotyping across the full allele frequency spectrum in Asians, a custom 
panel of ~30,000 missense or nonsense variants identified from 3 independent Asian sequencing data 
sets of ~1,000 Chinese samples were integrated into the Asian Exomechip. Additionally, a custom set 
of common variants selected for GWAS follow-up or fine mapping studies was also included. 
Genotype calling was conducted by the GenTrain version 2.0 in GenomeStudio V2011.1 (Illumina). 
We first conducted manual inspection of genotype clusters for over 55,000 variants that had a 
GenTrain score <0.8; or with high missingness (>1%); or were shown to have poor genotype 
clustering in exome chip genotyping of >9000 individuals by collaborators [13, 18]. A total of 4550 
variants with poor genotype clustering were removed. Individual-level quality control (QC) was 
conducted with regard to gender mismatch, duplication, biological relatedness, and possible sample 
contamination. A principal component (PC) analysis was conducted to examine for the existence of 
non-Chinese samples using a panel of >20,000 independent common SNPs (MAF>0.05), with outliers 
excluded from the analysis.  For SNP-level QC, we excluded 217,455 SNPs with MAF<0.1%, of 
which 179,107 SNPs are monomorphic; 154 SNPs which deviated from Hardy-Weinberg Equilibrium 
(HWE) with p<1x10-5 in controls; 3854 SNPs with >2% missingness; and 8,086 SNPs that were 
originally designed for the purpose of QC, including the fingerprint SNPs for sample tracking, 
ancestry informative markers (AIMs) for distinguishing Europeans from native and African 
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Americans, and grid SNPs for the identification of identity by descent segments. After QC measures, 
a total of 5640 participants and 77,468 variants were included in the association analysis.  
 
Replication stage:  
In the replication stage, we genotyped all SNPs which achieved pdiscovery<5x10
-4 and with potential 
functional relevance, except CDKN2B-AS1/DMRTA1 rs10965250 and KCNQ1 rs2237896, which had 
been previously reported to be of genome-wide significance (p<5x10-8) in GWAS [1], and also 
reached exome-wide significance (pdiscovery<6.45x10
-7 [=0.05/77,468]) in the current study. By SNPs 
with potential functional relevance, we refer to SNPs at or near genes that showed protein-protein 
interactions, or shared same pathway with known type 2 diabetes susceptibility genes, or were 
implicated in the pathogenesis of diabetes. These included PAX4 rs2233580, CDKAL1 rs10440833, 
FGFR1 rs2288696, ANKRD55/MAP3K1 rs456867, IGF2BP2 rs11711477, TTBK2 rs56017612 and 
DUSP26/UNC5D rs4739563, HCG27/HLA-C rs3869115, SCN1B rs67701503, DAP rs267939, 
CSN1S1 rs10030475, ZNF283/ZNF404 rs138993781, STAB1 rs740903, CARNS1 rs868167, and 
PDPN chr1:13937002. All 15 selected SNPs were then genotyped using the MassARRAY Sequenom 
platform (San Diego, CA, USA) at the Beijing Genomics Institute (BGI), Beijing. Four SNPs which 
either showed low genotyping call rate (<90%; PDPN chr1:13937002 and IGF2BP2 rs11711477); or 
deviated from HWE in controls (pHWE<0.003=0.05/15; CDKAL1 rs10440833 and SCN1B rs67701503) 
in the replication study were excluded from further analysis. Thus for the final analysis, a total of 11 
SNPs were included. PAX4 rs2233580 did not deviate from HWE in controls and was therefore 
retained in the analysis, even though it was significantly deviated from HWE in the case group 
(PHWE<0.003). PAX4 has been implicated in the pathogenesis of type 2 diabetes [19], and it is 
recognised that a true association can lead to deviation from HWE in cases [20]. The average 
genotyping call rate of these SNPs was 98.2%. 
 
Data analysis 
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All statistical analyses in the discovery and replication stages were conducted using PLINK version 
1.9 [21]. In the discovery stage, multiple logistic regression analysis with adjustment for age, sex and 
first 2 PCs was employed to examine for the associations with type 2 diabetes, under the additive 
genetic model. To assess the adiposity independent association of the top SNPs with type 2 diabetes, 
we further included body mass index (BMI) in the multiple logistic regression model. Exome-wide 
significance was defined as p<6.45x10
-7
 (=0.05/77,468). To address the between-SNP linkage 
disequilibrium (LD), the p-value informed LD based clumping approach with the “--clump” command 
implemented in PLINK was conducted. The index SNP had the most significant p-value from each 
clumped association region. Each index SNP formed clumps with other variants which were in LD 
with the index SNP (r2≥0.2) and were within ± 500kb from the index SNP. The association between 
PAX4 rs2233580 and age of diabetes diagnosis was examined by univariate linear regression analysis. 
In the replication stage, age and sex were included as covariates in the multiple logistic regression 
model to assess for associations with type 2 diabetes. A Bonferroni corrected one-tailed p-value 
<4.54x10
-3
 (=0.05/11) was used as the threshold for successful replication. Meta-analysis of the 
association results of the discovery and replication stages were conducted using METAL [22]. Inverse 
variance fixed-effect method was employed to pool the summary statistics of the two stages and 
heterogeneity of effect was assessed using Cochran’s Q-test and I
2
 index. 
 
Variants annotation and in silico functional analysis 
Function of variants and protein changes for non-synonymous SNPs were annotated by KGGSeq [23] 
according to the RefGene annotation. The pathogenic potential of the non-synonymous variants were 
assessed through various deleteriousness and conservation prediction tools implemented in KGGseq, 
including SIFT [24] and PolyPhen [25].  
 
Asian-specific variants 
Page 14 of 33
For Peer Review
11 
 
Variants were classified as “Asian-specific” if they were monomorphic in both the European and 
African populations but polymorphic (MAF>0) in the Asian population, according to the 1000 
Genomes Project [11]. 
 
Results 
 
A total of 5640 Chinese (Hong Kong) participants were genotyped using a custom Asian Exomechip 
(Table 1). Single variant association analysis was performed to assess the associations with type 2 
diabetes for 77,468 polymorphic variants (Figure 1). Of these, 48% alter protein composition and 21% 
were Asian-specific variants with MAF between 0.1 to 5%.  
 
In the discovery stage, single variant association analysis was conducted in 3652 cases and 1988 
controls, adjusted for age, sex and the first 2 PCs. We detected 34 index SNPs within 32 loci 
significantly associated with type 2 diabetes at pdiscovery<5x10
-4
 (ESM Table 2), of which, 3 variants 
reached exome-wide significance (pdiscovery<6.45x10
-7) (Table 2). These included the known 
associations at CDKN2B-AS1/DMRTA1 rs10965250 (pdiscovery=5.93x10
-8, OR[95%CI]:0.80[0.74, 0.87]) 
and KCNQ1 rs2237896 (pdiscovery=1.82x10
-7
; OR[95%CI]:0.80[0.73, 0.87]) reported in previous 
GWAS, as well as an Asian-specific variant, rs2233580 (p.Arg192His), of PAX4 which showed an 
exome-wide significant association with type 2 diabetes (pdiscovery=1.75x10
-7; OR[95%CI]:1.39[1.23, 
1.56]). As PAX4 is a known gene for maturity onset diabetes of the young (MODY) [26], we further 
examined its association with age of diabetes diagnosis. The risk allele (T) of rs2233580 was found to 
be significantly associated with younger age of diabetes diagnosis (p=6.01x10-4; beta[95%CI]: -1.45[-
2.28, -0.62]; Mean age of diagnosis ± standard deviation [years]: TT:52±13; CT:53±13; CC:54±13). 
In addition, we also identified several loci not previously reported to be associated with type 2 
diabetes: FGFR1 rs2288696 (pdiscovery=2.29x10
-5; OR:[95%CI]:0.73[0.63, 0.85]), TTBK2 rs56017612 
(pdiscovery=7.40x10
-5
; OR[95%CI]:0.72[0.61, 0.85]) and DUSP26/UNC5D rs4739563 
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(pdiscovery=7.48x10
-5; OR:[95%CI]:0.80[0.0.72, 0.90]). Association of all SNPs remained significant 
after further adjustment for BMI (ESM Table 2).  
 
In the replication stage, 11 of the 15 selected SNPs passed QC and were analysed in 3537 cases and 
8825 controls. Replication and combined association results of these SNPs are shown in Table 3. Of 
these, 8 of them showed consistent direction of effects. Only the association of the PAX4 missense 
variant rs2233580 with type 2 diabetes was successfully replicated (one-tailed preplication=1.22x10
-9; 
OR[95%CI]:1.28[1.18, 1.39]; remained significant after Bonferroni correction). Meta-analysis of the 
association results gave a genome-wide significant association, with no evidence of heterogeneity in 
effect size (pmeta=3.74x10
-15, OR[95%CI]:1.31[1.23, 1.40]; I2=10, pheterogeneity=0.292). The associations 
of FGFR1 rs2288696, TTBK2 rs56017612 and DUSP26/UNC5D rs4739563 were not significant in 
the replication cohort. However, the direction of effects for both FGFR1 rs2288696 and TTBK2 
rs56017612 were consistent with those from the discovery stage. A modest association was observed 
at a missense variant of CSN1S1 (rs10030475 [p.Pro137Thr]; one-tailed preplication=7.5x10
-3
, 
OR[95%CI]:0.93[0.87, 0.99]). However, this association did not pass Bonferroni correction for 
multiple testing in the replication stage. 
 
Conclusions 
 
The present study reports the first exome-chip association analysis on type 2 diabetes in a Chinese 
population. By genotyping 5640 Chinese participants using a custom Asian Exome-chip which 
interrogated 77,468 polymorphic SNPs, we identified the association of an Asian-specific coding 
variant in PAX4 and replicated the associations of some known type 2 diabetes-susceptibility loci. We 
also detected a few possible candidates which showed potential functional relevance in the 
pathogenesis of type 2 diabetes, such as TTBK2, FGFR1 and CSN1S1.   
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The identification of the Asian-specific and probably damaging variant of PAX4 is the major finding 
of this study. PAX4 encodes a member of the PAX family of paired-homeodomain factor. PAX4 
functions as a transcription repressor and plays a crucial role in pancreatic beta-cell function and 
development [27]. It also plays a role in beta-cell proliferation and survival [28, 29]. The 
heterozygous PAX4 knockout mice harbour less mature pancreatic beta- and delta-cells but with 
numerous abnormally clustered alpha-cells, indicating the essential role of PAX4 in the differentiation 
of beta- and delta-cell lineages [30]. PAX4 has been shown to repress transcriptional activity of 
insulin [19] and glucagon [31] promoters. PAX4 is located at 7q32, a region reported to be associated 
with type 2 diabetes in previous GWAS of Asians [32, 33]. An intergenic variant rs6467136 located 
near GRIP and GCC1-PAX4 was reported to be associated with type 2 diabetes in a meta-analysis of 8 
GWAS studies in East Asians [32]; and rs10229583 located downstream of PAX4 was identified in a 
GWAS for type 2 diabetes in a Chinese population [33]. Such observations, together with our findings, 
suggested that the effect of PAX4 may be more evident in East Asians than in other populations. Both 
of these SNPs appear to be independent to the missense variant rs2233580 identified in the current 
study. rs2233580 shows very low LD with both rs6467136 (r2=0.03) and rs10229583 (r2=0.02). The 
association of rs6467136 was not significant (pdiscovery=0.284). Data for rs10229583 was not available 
for analysis. Our findings have provided evidence that PAX4 is a possible effector gene at 7q32, a 
GWAS locus for type 2 diabetes. Our exome-chip could achieve 50% coverage of the coding variants 
within this gene region. Nonetheless, we were unable to eliminate the possibility that the association 
of rs2233580 identified in the current study resulted from tagging of other causative coding variants 
which were not covered by our exome-chip.  On the other hand, its functional significance, as 
demonstrated by in silico [24, 25] and in vitro [34, 35] analyses, suggests that this SNP is likely to be 
the causative variant. While in silico analysis of the 2 previously reported intergenic variants was 
unable to give a clue to their functional relevance (RegulomeDB score=5 for rs10229583; 6 for 
rs6467136), rs2233580 was predicted to be damaging by multiple prediction tools [24, 25] (SIFT 
score=0; PolypPhen2 HDIV score=1; Polyphen2 HVAR score=0.99). In vitro study showed that the 
transcriptional repressor activities of PAX4 p.Arg192His on human insulin and glucagon promoters 
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were reduced when compared with the wild-type PAX4 [34]. The Arg192 residue is highly conserved 
across different species, including human, mouse, rat and chimpanzee and this residue has been 
shown to make a direct contact with the major groove of the DNA binding sequence [35]. An amino 
acid change in the homeodomain of PAX4 may cause a defect in its transcriptional activity. It has 
been proposed that this variant may affect diabetes risk through its effect on beta-cell proliferation in 
adult pancreas, or beta-cell differentiation and maturation during development which leads to beta-cell 
mass reduction [34]. While rs2233580 has a frequency of ~10% among Asian populations, this 
variant was found to be monomorphic in Europeans and Africans, suggesting interrogation in less 
studied non-European populations would facilitate the identification of novel population-specific 
associations. Our finding of an Asian-specific variant also has implications on the construction of 
polygenic genetic scores to predict type 2 diabetes in Asian populations.  
 
Our observation of the significant association of PAX4 rs2233580 with type 2 diabetes was in 
agreement with findings from a large-scale whole-genome/exome sequencing study conducted by the 
GoT2D and T2D-GENES consortia [36], recently published during the review process of our 
manuscript. rs2233580 was reported to be associated with type 2 diabetes exclusively in 2165 East 
Asian individuals at genome-wide significance (p=9.3x10
-9
), and this association was further 
replicated in 3 independent East Asian cohorts [36].  Mutations in PAX4 have been found to cause the 
rare monogenic form MODY in Thais [26]. On the other hand, common variants of a number of 
established MODY genes have been found to be associated with type 2 diabetes, including GCK, 
HNF1-aplha, HNF4-alpha, HNF1-beta, and PDX1 [37-39]. Findings from the current study and those 
reported by the GoT2D and T2D-GENES consortia suggest that PAX4 also harbours common variants 
that confer susceptibility to type 2 diabetes. Interestingly, in a previous GWAS of East Asians, the 
risk allele of a common variant, rs10229583, located downstream of PAX4, was reported to be 
associated with higher risk of type 2 diabetes and a younger age of diagnosis [33]. Among the 3652 
cases in the current study, individuals who carried the risk allele (T) of the PAX4 missense variant 
rs2233580 were also significantly younger at the time of diagnosis. In contrast, the GoT2D and T2D-
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GENES consortia reported no significant association between rs2233580 and age of diagnosis in a 
total of 1619 cases from the 3 independent cohorts of East Asian ancestry (Hong Kong Chinese, 
Korean, and Singapore Chinese) [36]. This contradictory observation could be attributable to the 
much larger sample size of the current study which provided sufficient power to detect the association 
(ESM Table 3). Furthermore, study heterogeneity caused by different ascertainment criteria of type 2 
diabetes cases between studies may have also contributed to the discordant observations. A meta-
analysis of our data with those of the 3 independent cohorts has provided evidence to support the 
association of PAX4 rs2233580 with younger age of diagnosis (pmeta=0.007; z-score= -2.717; I
2=58.5, 
pheterogeneity=0.065) (ESM Table 3).  
 
Although unable to reach genome/exome-wide significance, the potential functions of TTBK2, 
FGFR1 and CSN1S1 have made them possible candidates for T2DM. TTBK2 (Tau-tubulin-kinase 2) 
is a serine/threonine kinase known to phosphorylate tau and tubulin [40]. TTBK2 is involved in the 
regulation of a sodium-dependent glucose transporter, SGLT1 [41], which is responsible for the 
absorption of glucose and galactose in the intestine and is involved in the renal reabsorption of 
glucose in kidney [42]. Depletion of TTBK2 has been shown to decrease SGLT1 stability in the cell 
membrane and lead to loss of glucose transport capacity in Xenopus oocytes [41]. Mice with 
attenuated FGFR1 signalling exhibited a reduced number of beta-cells, impaired expression of 
glucose transporter 2, enhanced proinsulin content in beta-cells and developed diabetes with age [43]. 
FGFR1 is the primary receptor of fibroblast growth factor 21 (FGF21), and hence regulates FGF21 
responsiveness. FGF21 has shown beneficial metabolic effects in animals and humans [44]. Our team 
previously demonstrated that high FGF21 levels could predict type 2 diabetes development [15]. The 
paradoxical increase in FGF21 levels in patients with type 2 diabetes suggest that FGF21 resistance 
may play a role in the pathogenesis of type 2 diabetes [44]. Our finding that a variant of FGFR1 is 
associated with type 2 diabetes is supportive of such a possibility. Casein Alpha S1 (CSN1S1) is a 
member of the casein family. CSN1S1 has been shown to possess proinflammatory properties such as 
the upregulation of IL-1beta [45], the causative role of which in the loss of beta-cell mass in type 2 
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diabetes has been suggested by data from animal studies and clinical trials [46]. Given their potential 
functional relevance in the pathogenesis of type 2 diabetes, more detailed investigation of these genes, 
such as deep sequencing analysis, is warranted. 
 
A potential limitation of the present study was the under-representation of rare functional variants 
specific to the Chinese populations in the exome-chip. With an attempt to ameliorate this limitation, 
we included additional coding variants to augment the coverage. Small sample size has always been a 
major limitation hindering the identification of rare variants, as demonstrated in this study. The 
sample size of the discovery stage is relatively small and therefore lacks statistical power to detect 
variants with modest effect size or very low frequency. Future large-scale meta-analysis with other 
Asian cohorts may serve to identify more functional variants that are specific to our population. 
Trans-ethnic meta-analysis will help to enhance the fine-mapping resolution of causal variants. 
Another limitation of the present study could be the SNP selection for replication.  
 
In summary, the significant association of an Asian-specific coding variant rs2233580 (p.Arg192His) 
with type 2 diabetes was identified in an exome-chip association analysis in a Chinese population. 
Our findings has provided compelling evidence that PAX4 could be a possible effector gene of the 
7q32 locus and supported its involvement in the pathogenesis of type 2 diabetes.   
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Figure 1. Manhattan plot of discovery stage results. 
 
Figure legend: The y-axis represents the –log10 p-value, and the x-axis represents the 77,468 analysed 
SNPs. The grey dash horizontal line indicates the exome-wide significance (6.45x10-7). The diamond 
symbol indicates the exome-wide significant SNPs.  
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Table 1. Clinical characteristics of study participants in the discovery stage. 
  Controls Cases p-value 
Number 1988 3652 - 
Male, % 56.4 60.9 <0.001 
Age, year 58.7 ± 12.1 64.8 ± 11.8 <0.001 
Fasting glucose, mmol/l 5.1 ± 0.6 7.6 ± 2.5 <0.001 
Body mass index, kg/m
2
 24.2 ± 3.7 25.9 ± 4.0 <0.001 
Waist circumference, cm 
M: 86.3 ± 8.4 M: 91.5 ± 10.2 <0.001 
F:79.1 ± 9.1 F:86.3 ± 10.9 <0.001 
Coronary artery disease, % 37.2 43.8 <0.001 
Hypertension, % 40.3 85.5 <0.001 
Use of anti-hypertensive drug, % 31.5 83.0 <0.001 
Use of lipid lowering drug, % 37.5 65.6 <0.001 
Ever Smoker, % 34.4 35.9 0.251 
Data as mean ± standard deviation. M: Male; F: Female; T2DM, type 2 diabetes.
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Table 2. Association results of SNPs reaching exome-wide significance (p<6.45x10-7) in the discovery stage. 
      MAF    
Nearest gene(s) SNP Position Annotation A1 A2 Cases Controls OR(95%CI) p-value
a
 p-value
b
 
Asian-specific variant           
     PAX4 rs2233580 7:127253550 p.Arg192His T C 0.145 0.113 1.39(1.23-1.56) 1.75 x 10-7 7.62 x 10-6 
Established type 2 diabetes susceptibility variants        
     CDKN2B-AS1/DMRTA1 rs10965250 9:22133284 intergenic A G 0.384 0.430 0.80(0.74-0.87) 5.93 x 10-8 8.80 x 10-10 
     KCNQ1 rs2237896 11:2858440 intronic A G 0.311 0.359 0.80(0.73-0.87) 1.82 x 10
-7
 1.53 x 10
-8
 
A1: Minor allele; A2: Major allele; MAF: Minor allele frequency. The ORs are reported with respect to the minor allele.  
a
Adjusted for age, sex, PC1 and PC2. 
b
Adjusted for age, sex, BMI, PC1 and PC2.  
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Table 3. Replication and combined association results. 
A1: Minor allele; Dir: Direction of effect. The ORs are reported with respect to the minor allele. aAdjusted for age and sex. One-tailed p-value: For effects in 
the same direction as in the discovery stage analysis, one-tailed p-values were calculated as (p/2); for effects in opposite direction, one-tailed p-values were 
calculated as (1 - p/2). SNP that survived Bonferroni correction for multiple testing in the replication analysis is underlined.   
   
 Discovery 
Hong Kong 
(3652cases VS 1988controls) 
 Replication 
Guangzhou 
(3537cases VS 8825controls) 
 Combined 
Hong Kong + Guangzhou 
(7189cases VS 10813controls) 
Gene(s) SNP A1 
 
OR(95%CI) p-valuea 
 
OR(95%CI) 
One-tailed 
p-valuea 
 
Dir OR(95%CI) p-valuea 
PAX4 rs2233580 T 
 
1.39(1.23-1.56) 1.75 x 10-7 
 
1.28(1.18-1.39) 1.22x10-9 
 
+ + 1.31(1.23-1.40) 3.74x10-15 
FGFR1 rs2288696 A 
 
0.73(0.63-0.85) 2.29 x 10-5 
 
0.98(0.88-1.09) 0.350 
 
– – 0.88(0.81-0.96) 4.57x10-3 
ANKRD55/MAP3K1 rs456867 T 
 
0.84(0.77-0.91) 4.78 x 10-5 
 
0.99(0.93-1.05) 0.363 
 
– – 0.94(0.89-0.98) 8.57x10-3 
TTBK2 rs56017612 C 
 
0.72(0.61-0.84) 7.40 x 10-5 
 
0.90(0.80-1.02) 0.046 
 
– – 0.83(0.75-0.92) 2.11x10-4 
DUSP26/UNC5D rs4739563 T 
 
0.80(0.72-0.90) 7.48 x 10-5 
 
1.00(0.93-1.08) 0.518 
 
– + 0.93(0.87-0.99) 0.020 
HCG27/HLA-C rs3869115 C 
 
0.81(0.73-0.90) 1.04 x 10-4 
 
0.99(0.92-1.07) 0.418 
 
– – 0.93(0.87-0.99) 0.016 
DAP rs267939 A 
 
0.79(0.69-0.89) 1.85 x 10-4 
 
1.01(0.92-1.10) 0.545 
 
– + 0.92(0.86-0.99) 0.035 
CSN1S1 rs10030475 T 
 
0.85(0.78-0.92) 1.86 x 10-4 
 
0.93(0.87-0.99) 7.5x10-3 
 
– – 0.90(0.85-0.94) 3.28x10-5 
ZNF283/ZNF404 rs138993781 G 
 
0.27(0.13-0.55) 2.93 x 10-4 
 
0.69(0.34-1.39) 0.148 
 
– – 0.43(0.26-0.71) 1.03x10-3 
STAB1 rs740903 T 
 
1.19(1.08-1.31) 3.02 x 10-4 
 
1.00(0.94-1.07) 0.450 
 
+ + 1.06(1.01-1.12) 0.030 
CARNS1 rs868167 A 
 
0.67(0.54-0.83) 3.33 x 10
-4
 
 
1.05(0.90-1.23) 0.730 
 
– + 0.90(0.79-1.02) 0.109 
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Figure 1. Manhattan plot of discovery stage results.  
 
Figure legend: The y-axis represents the –log10 p-value, and the x-axis represents the 77,468 analysed 
SNPs. The grey dash horizontal line indicates the exome-wide significance (6.45x10-7). The diamond symbol 
indicates the exome-wide significant SNPs.  
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ESM Table 1. Clinical characteristics of study participants in the replication stage. 
  
Controls Cases p-value 
Number 8825 3537 - 
Male, % 22.9 22.7 0.882 
Age, year 63.5 ± 7.1 65.9 ± 6.8 <0.001 
Fasting glucose, mmol/l 5.0 ± 0.01 7.1 ± 2.5 <0.001 
Haemoglobin A1c, % 5.8 ± 0.4 7.0 ± 1.4  <0.001 
Haemoglobin A1c, mmol/mol 39.5 ± 4.5 43.3 ± 15.1  <0.001 
Body mass index, kg/m2 23.3 ± 3.2 24.9 ± 3.5 <0.001 
Waist circumference, cm M:84.6 ± 9.0 F:79.6 ± 8.7 
M:87.2 ± 9.6 
F:82.7 ± 9.4 
<0.001 
<0.001 
Coronary artery diseasea, % 5.8 10.4 <0.001 
Hypertensionb, % 25.8 51.0 <0.001 
Use of anti-hypertensive drug, % 20.8 45.8 <0.001 
Use of lipid lowering drug, % 4.2 6.1 <0.001 
Ever smoker, % 18.3 18.8 0.556 
Data as mean ± standard deviation. aSelf-reported CAD. bSelf-reported hypertension. 
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      MAF    
Gene(s) SNP Position Annotation A1 A2 Cases Controls OR(95%CI) p-valuea p-valueb 
Known loci           
    CDKN2B-AS1/DMRTA1 rs10965250 9:22133284 intergenic A G 0.384 0.430 0.80(0.74-0.87) 5.93 x 10-8 8.80 x 10-10 
    PAX4 rs2233580c 7:127253550 p.Arg192His T C 0.145 0.113 1.39(1.23-1.56) 1.75 x 10-7 7.62 x 10-6 
    KCNQ1 rs2237896 11:2858440 intronic A G 0.311 0.359 0.80(0.73-0.87) 1.82 x 10-7 1.53 x 10-8 
    CDKAL1 rs10440833 c 6:20688121 intronic A T 0.385 0.340 1.22(1.12-1.33) 2.71 x 10-6 3.66 x 10-7 
    ANKRD55/MAP3K1 rs456867 c 5:55811092 intronic T C 0.330 0.366 0.84(0.77-0.91) 4.78 x 10-5 1.65 x 10-4 
    IGF2BP2 rs11711477 c 3:185526690 intronic A T 0.263 0.226 1.21(1.11-1.33) 4.88 x 10-5 1.17 x 10-4 
   CDC123/CAMK1D rs10906115 10:12314997 intergenic G A 0.375 0.405 0.86(0.79-0.93) 3.46 x 10-4 3.03 x 10-4 
    HNF1B rs7501939 17:36101156 intronic T C 0.238 0.204 1.19(1.08-1.31) 3.77 x 10-4 1.04 x 10-4 
    ANKRD55/MAP3K1 rs13178412 5:55831021 p.Tyr23His G A 0.047 0.061 0.73(0.62-0.87) 4.66 x 10-4 2.39 x 10-4 
    CDKN2B-AS1/DMRTA1 rs10965251 9:22134029 intergenic A G 0.072 0.087 0.77(0.66-0.89) 4.86 x 10-4 3.18 x 10-4 
Novel loci           
    FGFR1 rs2288696 c 8:38286225 intronic A G 0.069 0.091 0.73(0.63-0.85) 2.29 x 10-5 2.21 x 10-5 
    TTBK2 rs56017612 c 15:43086885 p.Thr313Ala C T 0.054 0.072 0.72(0.61-0.84) 7.40 x 10-5 1.71 x 10-3 
    DUSP26/UNC5D rs4739563 c 8:34247995 intergenic T C 0.148 0.174 0.80(0.72-0.90) 7.48 x 10-5 2.35 x 10-4 
    PPP2R2B/STK32A rs6893679 5:146542753 intergenic A G 0.322 0.289 1.19(1.09-1.30) 1.02 x 10-4 5.77 x 10-3 
    HCG27/HLA-C rs3869115 c 6:31204694 intergenic C G 0.162 0.193 0.81(0.73-0.90) 1.04 x 10-4 1.00 x 10-4 
    SCN1B rs67701503 c 19:35524939 p.Ser248Arg A C 0.206 0.237 0.83(0.75-0.91) 1.32 x 10-4 7.16 x 10-4 
    SAMD4A/GCH1 rs8022503 14:55265828 intergenic T C 0.312 0.277 1.18(1.09-1.29) 1.57 x 10-4 1.21 x 10-3 
    PTPRQ rs6539524 12:80935345 p.Phe1056Leu C T 0.251 0.220 1.20(1.09-1.32) 1.82 x 10-4 2.26 x 10-3 
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    DAP rs267939 c 5:10752315 intronic A G 0.099 0.123 0.79(0.69-0.89) 1.85 x 10-4 1.88 x 10-4 
    CSN1S1 rs10030475 c 4:70807771 p.Ala117Val T C 0.277 0.312 0.85(0.78-0.92) 1.86 x 10-4 1.29 x 10-3 
    KIAA1755 rs3746471 20:36841914 p.Arg1045Trp A G 0.430 0.467 0.86(0.79-0.93) 1.93 x 10-4 1.68 x 10-4 
    OR4E2/DAD1 rs10140810 14:22392626 intergenic C A 0.473 0.435 1.17(1.08-1.26) 1.96 x 10-4 2.92 x 10-3 
    ACN9/TAC1 rs7791918 7:97207509 intergenic T G 0.420 0.380 1.17(1.08-1.26) 2.23 x 10-4 1.15 x 10-4 
    PPP1R3G/LYRM4 rs685187 6:5106807 ncRNA C T 0.109 0.131 0.80(0.71-0.90) 2.62 x 10-4 2.26 x 10-2 
    ZNF283/ZNF404 rs138993781 c 19:44366936 intergenic G A 0.002 0.005 0.27(0.13-0.55) 2.93 x 10-4 3.75 x 10-3 
    STAB1 rs740903 c 3:52548818 p.Cys1260Cys T C 0.251 0.222 1.19(1.08-1.31) 3.02 x 10-4 2.71 x 10-5 
    SLC38A5 rs17281188 X:48317386 p.Met451Thr G A 0.077 0.095 0.73(0.62-0.87) 3.05 x 10-4 2.02 x 10-3 
    SLC13A1 rs2140516 7:122809234 p.Asn174Ser C T 0.337 0.374 0.86(0.79-0.93) 3.31 x 10-4 7.66 x 10-4 
    CARNS1 rs868167 c 11:67186271 p.Pro137Thr A C 0.029 0.041 0.67(0.54-0.83) 3.33 x 10-4 2.83 x 10-4 
    LOC284294/CDH7 rs531795 18:62873393 intergenic A C 0.475 0.500 0.86(0.80-0.94) 3.85 x 10-4 1.61 x 10-4 
    TTBK2 rs6493068 15:43170793 p.Leu8Pro G A 0.402 0.431 0.86(0.80-0.94) 3.96 x 10-4 1.24 x 10-2 
    ULK4 rs1795316 3:41531910 intronic G T 0.377 0.344 1.16(1.07-1.26) 4.32 x 10-4 6.78 x 10-4 
    PDPN chr1:13937002 c 1:13937002 p.His66Tyr T C 0.001 0.004 0.18(0.07-0.47) 4.46 x 10-4 8.32 x 10-4 
    NR3C2/DCLK2 rs6826460 4:149605653 intergenic G A 0.274 0.305 0.85(0.78-0.93) 4.69 x 10-4 9.87 x 10-4 
A1: Minor allele; A2: Major allele; A1: Minor allele; A2: Major allele. The ORs are reported with respect to the minor allele. aAdjusted for age, sex, PC1 and 
PC2. bAdjusted for age, sex, BMI, PC1 and PC2. SNPs with exome-wide significance (p<6.45x10-7) are underlined. cSNPs followed-up in the replication 
analysis. 
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ESM Table 3. Distribution of mean age of diagnosis by PAX4 rs2233580 genotypes in the current 
study and 3 independent cohorts  
 
Mean age of diagnosis ± S.D (years)   
Study 
No. of 
Cases CC CT TT 
 
z-score p-value 
Hong Kong Chinesea: 
HKU-TRS 
3652 2666 910 76  - 
 54.37±12.63 52.73±13.02 52.37±12.69 -3.431 6.01x10-4 
 
      
Singapore Chineseb: 
Singapore Diabetes 
Cohort Study and 
Singapore Prospective 
Study Programme 
560 417 130 13  - 
 57.12±12.55 56.47±13.03 52.40±12.18 -1.195 0.232 
 
      
Hong Kong Chinese b: 
Hong Kong Diabetes 
Registry (CUHK) 
489 314 153 22  - 
 36.41±9.49 36.80±10.13 32.14±6.58 0.931 0.351 
 
      
Koreanb:  
Seoul National 
University Hospital 
Diabetes Case Control 
Study (SNUH) 
570 458 98 14  - 
 50.38±9.67 51.61±11.52 51.20±10.90 0.742 0.458 
 
      
Combined 5271 - - - -2.717 0.007c 
S.D, standard deviation. a  Current study. b Reported in reference [1]. c p-value from a sample-size 
weighted meta-analysis by combining unadjusted p-values across studies using METAL [2] (I2=58.5, 
pheterogeneity=0.065).  
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